Dolutegravir Dosing for HIV Treatment
The standard dose of dolutegravir for HIV treatment is 50 mg once daily in treatment-naïve and treatment-experienced adults without integrase resistance, but this must be increased to 50 mg twice daily when co-administered with strong enzyme inducers such as rifampin, efavirenz, carbamazepine, or fosamprenavir/ritonavir 1, 2.
Standard Dosing
Adults
- 50 mg once daily for treatment-naïve and treatment-experienced, INSTI-naïve patients without enzyme inducers 2
- Can be taken with or without food 2
Pediatric Dosing
Weight-based dosing applies for children 2:
- 3 kg to <6 kg: 5 mg once daily
- 6 kg to <10 kg: 15 mg once daily
- 10 kg to <14 kg: 20 mg once daily
- 14 kg to <20 kg: 25 mg once daily
- 20 kg to <25 kg: 30 mg once daily
- ≥20 kg: 50 mg once daily
Dose Adjustments with Strong Enzyme Inducers
With Rifamycin-Containing Tuberculosis Treatment
For active tuberculosis with rifampin-containing regimens: increase to 50 mg twice daily (evidence rating: AIa) 1.
For latent tuberculosis treatment:
- With 1HP (daily isoniazid/rifapentine for 1 month): 50 mg twice daily (evidence rating: BIa) 1
- With 3HP (weekly isoniazid/rifapentine for 3 months): standard 50 mg once daily is sufficient (evidence rating: AIa) 1
The distinction between 1HP and 3HP is critical—1HP requires twice-daily dosing due to daily rifapentine exposure, while 3HP's weekly rifapentine allows standard once-daily dosing to maintain adequate dolutegravir concentrations 1.
With Other Strong Inducers
Increase to 50 mg twice daily when co-administered with 2:
- Efavirenz
- Carbamazepine
- Fosamprenavir/ritonavir
- Tipranavir/ritonavir
Avoid co-administration with 2:
- Nevirapine (insufficient data for dosing recommendations)
- St. John's wort (insufficient data)
- Oxcarbazepine, phenytoin, phenobarbital (insufficient data)
Critical Caveats for INSTI-Experienced Patients
For patients with integrase resistance or prior INSTI exposure with resistance mutations, avoid enzyme inducers entirely when possible 2. The lower dolutegravir exposures in these patients when combined with inducers may result in loss of therapeutic effect and development of resistance 2. If inducers cannot be avoided, use alternative combinations that do not include metabolic inducers.
Drug Interaction Management
Polyvalent Cations (Antacids, Calcium, Iron)
- Administer dolutegravir 2 hours before or 6 hours after antacids, laxatives, sucralfate, or buffered medications 2
- With food: calcium or iron supplements can be taken simultaneously with dolutegravir 2
- Fasting: separate by 2 hours before or 6 hours after 2
Etravirine
Do not use with etravirine unless co-administered with atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir 2.
Special Populations
Renal Impairment
No dose adjustment needed for mild-to-moderate renal impairment. Inadequate data for patients requiring dialysis 2.
Hepatic Impairment
No dose adjustment needed for moderate hepatic impairment (Child-Pugh B). No data for severe hepatic impairment (Child-Pugh C) 2.
Pregnancy and Neonates
Limited data available; standard dosing typically maintained but requires close monitoring 3.
Monitoring Considerations
While therapeutic drug monitoring is not routinely required, it can guide dosing decisions when strong inducers are used, particularly in INSTI-experienced patients 4. Dolutegravir trough concentrations should remain above 64 ng/mL (protein-binding-adjusted IC90) for efficacy 5.
The 2025 International Antiviral Society-USA guidelines provide the highest level of evidence (AIa rating) for twice-daily dosing with rifamycin-containing regimens for active tuberculosis and 3HP for latent tuberculosis, reflecting robust clinical trial data showing 97% viral suppression rates at 24 weeks 1.